Latest news
Iconovo receives a significant order from Japanese TOA Pharmaceuticals Co., Ltd.
Iconovo receives a significant order from Japanese TOA Pharmaceuticals Co., Ltd.
The innovative Swedish medical technology provider Iconovo AB announced…
Interview with Dr Orest Lastow November 2018 (only in Swedish)
Skånebolaget Iconovo utvecklar inhalatorer med tillhörande läkemedelsberedning som främst används för att behandla Astma och KOL men Iconovo besitter…
Press releases
Apr 15, 2020, 09:40
News
IR
Swedish
Corporate Information
Other Corporate Information
Apr 08, 2020, 16:15
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 07, 2020, 10:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 27, 2020, 15:18
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 20, 2020, 09:15
News
IR
Swedish
Regulatory
Corporate Information
Other Corporate Information
Mar 19, 2020, 14:18
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 13, 2020, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 11, 2020, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Feb 14, 2020, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 10, 2020, 19:39
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Jan 10, 2020, 08:22
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
